References
1. World Health Organisation. Fact sheet - Obesity and overweight. Published 2020. Accessed May 20, 2020. https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
2. Adams K, Schatzkin A, Harris T, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old.N Engl J Med . 2006;(355):763-778. doi:10.1056/NEJMoa1109071
3. Bogers R, Bemelmans W, Hoogenveen R, et al. Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels. Arch Intern Med . 2007;167(16):1720-1728.
4. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med . 2013;273(3):219-234. doi:10.1111/joim.12012
5. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med . Published online 2003:1695-1702.
6. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database of Systematic Reviews. Cochrane Collab . 2014;(8):244. doi:10.1002/14651858.CD003641.pub4.www.cochranelibrary.com
7. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored By American Association of Clinical Endocrinologists/American College of Endocrinology,. Endocr Pract . 2019;25(12):1346-1359. doi:10.4158/GL-2019-0406
8. Zenténius E, Andersson-Assarsson JC, Carlsson LMS, Svensson PA, Larsson I. Self-Reported Weight-Loss Methods and Weight Change: Ten-Year Analysis in the Swedish Obese Subjects Study Control Group.Obesity . 2018;26(7):1137-1143. doi:10.1002/oby.22200
9. Reges O, Greenland P, Dicker D, et al. Association of bariatric surgery using laparoscopic banding, roux-en-y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA - J Am Med Assoc . 2018;319(3):279-290. doi:10.1001/jama.2017.20513
10. Lindekilde N, Gladstone BP, Lübeck M, et al. The impact of bariatric surgery on quality of life: A systematic review and meta-analysis.Obes Rev . 2015;16(8):639-651. doi:10.1111/obr.12294
11. Angrisani L, Santonicola A, Iovino P, et al. IFSO Worldwide Survey 2016: Primary, Endoluminal, and Revisional Procedures. Obes Surg . 2018;28(12):3783-3794. doi:10.1007/s11695-018-3450-2
12. Smith C, Herkes S, Behrn K, Fairbanks V, Kelly K, Sarr M. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg . 1993;218:91-96.
13. Tolone S, Savarino E, de Bortoli N, et al. Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. J Gastrointest Surg . 2020;24(1):1-7. doi:10.1007/s11605-019-04406-7
14. Yska JP, Van Der Meer DH, Dreijer AR, et al. Influence of bariatric surgery on the use of medication. Eur J Clin Pharmacol . 2016;72(2):203-209. doi:10.1007/s00228-015-1971-3
15. Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M. Development and applications of a physiologically-based model of paediatric oral drug absorption. Eur J Pharm Sci . 2018;115(December 2017):57-67. doi:10.1016/j.ejps.2018.01.009
16. Kostewicz ES, Aarons L, Bergstrand M, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci . 2014;57(1):300-321. doi:10.1016/j.ejps.2013.09.008
17. Darwich AS, Henderson K, Burgin A, et al. Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol . 2012;74(5):774-787. doi:10.1111/j.1365-2125.2012.04284.x
18. Azran C, Wolk O, Zur M, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev . 2016;17(11):1050-1066. doi:10.1111/obr.12434
19. van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev . 2017;18(1):68-85. doi:10.1111/obr.12467
20. Montanha MC, Santos Magon TF, Souza Alcantara C, et al. Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux‐en‐Y gastric bypass bariatric subjects. Br J Clin Pharmacol . 2019;85(9):2118-2125. doi:10.1111/bcp.14023
21. Schulman AR, Chan WW, Devery A, Ryan MB, Thompson CC. Opened Proton Pump Inhibitor Capsules Reduce Time to Healing Compared With Intact Capsules for Marginal Ulceration Following Roux-en-Y Gastric Bypass.Clin Gastroenterol Hepatol . 2017;15(4):494-500.e1. doi:10.1016/j.cgh.2016.10.015
22. Lloret-Linares C, Luo H, Rouquette A, et al. The effect of morbid obesity on morphine glucuronidation. Pharmacol Res . 2017;118:64-70. doi:10.1016/j.phrs.2016.08.031
23. Brill MJ, Van Rongen A, Van Dongen EP, et al. The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients before and One Year after Bariatric Surgery. Pharm Res . 2015;32(12):3927-3936. doi:10.1007/s11095-015-1752-9
24. Mechanick JI, Youdim A, Jones DB, T G, L HD, Mcmahon M. Clinical Practice Guidelines for the Perioperative Nutritional. Obesity . 2013;21(0 1):S1-27. doi:10.1002/oby.20461.Clinical
25. Carr WRJ, Mahawar KK, Balupuri S, Small PK. An evidence-based algorithm for the management of marginal ulcers following Roux-en-Y gastric bypass. Obes Surg . 2014;24(9):1520-1527. doi:10.1007/s11695-014-1293-z
26. Hogben CAM, Schanker LS, Tocco DJ, Brodie BB. ABSORPTION OF DRUGS FROM THE STOMACH. II. THE HUMAN. J Pharmacol Exp Ther . 1957;120(4).
27. Mitrov-Winkelmolen L, van Buul-Gast MCW, Swank DJ, Overdiek HWPM, van Schaik RHN, Touw DJ. The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. Obes Surg . 2016;26(9):2051-2058. doi:10.1007/s11695-016-2065-8
28. Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole. Clin Pharmacokinet . 2011;50(11):725-734. doi:10.2165/11592630-000000000-00000
29. Krishna G, Moton A, Lei M, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother . 2009;53(3):958-966. doi:10.1128/AAC.01034-08
30. Gesquiere I, Hens B, Van der Schueren B, et al. Drug disposition before and after gastric bypass: fenofibrate and posaconazole. Br J Clin Pharmacol . 2016;60:1325-1332. doi:10.1111/bcp.13054
31. Carswell KA, Vincent RP, Belgaumkar AP, et al. The Effect of Bariatric Surgery on Intestinal Absorption and Transit Time. Obes Surg . 2014;24(5):796-805. doi:10.1007/s11695-013-1166-x
32. Dirksen C, Damgaard M, Bojsen-Møller KN, et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil . 2013;25(4). doi:10.1111/nmo.12087
33. Nguyen NQ, Debreceni TL, Burgstad CM, et al. Effects of Posture and Meal Volume on Gastric Emptying, Intestinal Transit, Oral Glucose Tolerance, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass. Obes Surg . 2015;25(8):1392-1400. doi:10.1007/s11695-014-1531-4
34. Wang G, Agenor K, Pizot J, et al. Accelerated Gastric Emptying but No Carbohydrate Malabsorption 1 Year After Gastric Bypass Surgery (GBP).Obes Surg . 2012;22(8):1263-1267. doi:10.1007/s11695-012-0656-6
35. Yska JP, Wanders JTM, Odigie B, et al. Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: A single oral dose study before and after surgery. Eur J Hosp Pharm . Published online 2019:1-6. doi:10.1136/ejhpharm-2018-001804
36. Gesquiere I, Darwich AS, Van der Schueren B, et al. Drug disposition and modelling before and after gastric bypass: immediate and controlled-release metoprolol formulations. Br J Clin Pharmacol . 2015;80(5):1021-1030. doi:10.1111/bcp.12666
37. Krieger CA, Cunningham JL, Reid JM, et al. Comparison of Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in Obese Patients Before and After Gastric Bypass Surgery.Pharmacotherapy . 2017;37(11):1374-1382. doi:10.1002/phar.2022
38. Hachon L, Reis R, Labat L, et al. Morphine and metabolites plasma levels after administration of sustained release morphine in Roux-en-Y gastric bypass subjects versus matched control subjects. Surg Obes Relat Dis . 2017;13(11):1869-1874. doi:10.1016/j.soard.2017.07.030
39. Dobner J, Kaser S. Body mass index and the risk of infection - from underweight to obesity. Clin Microbiol Infect . 2018;24(1):24-28. doi:10.1016/j.cmi.2017.02.013
40. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes . 2013;37(3):333-340. doi:10.1038/ijo.2012.62
41. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis . 2006;6(7):438-446. doi:10.1016/S1473-3099(06)70523-0
42. Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother . 2014;69(3):715-723. doi:10.1093/jac/dkt444
43. Hollenstein UM, Brunner M, Schmid R, Müller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes . 2001;25(3):354-358. doi:10.1038/sj.ijo.0801555
44. Miskowiak J, Andersen B, Nielsen VG. Absorption of oral penicillin before and after gastroplasty for morbid obesity. Pharmacology . 1985;31(2):115-120. doi:10.1159/000138106
45. Terry SI, Gould JC, McManus JPA, Prescott LF. Absorption of penicillin and paracetamol after small intestinal bypass surgery.Eur J Clin Pharmacol . 1982;23(3):245-248. doi:10.1007/BF00547562
46. Montanha MC, dos Santos Magon TF, de Souza Alcantara C, et al. Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects. Br J Clin Pharmacol . 2019;85(9):2118-2125. doi:10.1111/bcp.14023
47. Rocha MBS, De Nucci G, Lemos FN, et al. Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin. Obes Surg . 2019;29(3):917-927. doi:10.1007/s11695-018-3591-3
48. Kampmann JP, Klein H, Lumholtz B, Hansen JEM. Ampicillin and Propylthiouracil Pharmacokinetics in Intestinal Bypass Patients Followed Up to a Year after Operation. Clin Pharmacokinet . 1984;9(2):168-176. doi:10.2165/00003088-198409020-00004
49. Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol . 1984;24(11-12):523-527. doi:10.1002/j.1552-4604.1984.tb02762.x
50. Padwal RS, Ben-Eltriki M, Wang X, et al. Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother . 2012;67(9):2203-2206. doi:10.1093/jac/dks177
51. De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother . 2012;67(1):226-229. doi:10.1093/jac/dkr436
52. Rivas AB, Lopez-Picado A, Salas-Butrón M del R, et al. Effect of Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious effect? Eur J Clin Pharmacol . 2019;75(5):647-654. doi:10.1007/s00228-018-02623-8
53. Roy DJ, Langworthy DR, Thurber KM, Lorentz PA, Dierkhising RA, Mundi MS. Comparison of oral antibiotic failure rates in post-Roux-en-Y gastric bypass patients versus controls. Surg Obes Relat Dis . 2017;13(9):1524-1529. doi:10.1016/j.soard.2017.03.026
54. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther . 2011;89(5):718-725. doi:10.1038/clpt.2011.32
55. Jager NGL, Rosing H, Schellens JHM, Linn SC, Beijnen JH. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat . 2014;143(3):477-483. doi:10.1007/s10549-013-2826-1
56. Binkhorst L, Van Gelder T, Mathijssen RHJ. Individualization of tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther . 2012;92(4):431-433. doi:10.1038/clpt.2012.94
57. Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen Malabsorption after Roux-en-Y Gastric Bypass Surgery: Case Series and Review of the Literature. Pharmacotherapy . 2010;30(2):217. doi:10.1592/phco.30.2.217
58. Jager NGL, Koornstra RHT, Vincent AD, et al. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.BMC Cancer . 2013;13. doi:10.1186/1471-2407-13-612
59. Bauer KA. Pros and cons of new oral anticoagulants. Hematol am soc hematol educ Progr . Published online 2013:464-470.
60. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol . 2006;46(5):549-558. doi:10.1177/0091270006286904
61. Dewald TA, Becker RC. The pharmacology of novel oral anticoagulants.J Thromb Thrombolysis . 2014;37(2):217-233. doi:10.1007/s11239-013-0967-z
62. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement. J Clin Pharmacol . 2005;45(5):555-565. doi:10.1177/0091270005274550
63. Martin KA, Lee CR, Farrell TM, Moll S. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. Am J Med . 2017;130(5):517-524. doi:10.1016/j.amjmed.2016.12.033
64. Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br J Clin Pharmacol . 2017;83(7):1466-1475. doi:10.1111/bcp.13243
65. Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.Surg Obes Relat Dis . 2018;14(12):1890-1896. doi:10.1016/j.soard.2018.08.025
66. Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels.Thromb Res . 2018;163:190-195. doi:10.1016/j.thromres.2017.11.006
67. Lachant DJ, Uraizee I, Gupta R, Pedulla AJ. IJCRI International Journal of Case Reports and Images. Int J Case Reports Images Cover . 2015;6(11):663-664. doi:10.1681/ASN.2014100997
68. Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. J Cardiol Cases . 2013;8(1):e49-e50. doi:10.1016/j.jccase.2013.03.013
69. Miklič M, Mavri A, Vene N, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol . 2019;75(8):1069-1075. doi:10.1007/s00228-019-02693-2
70. Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet . 2015;385(9984):2288-2295. doi:10.1016/S0140-6736(14)61943-7
71. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol . 2014;63(4):321-328. doi:10.1016/j.jacc.2013.07.104
72. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol . 2016;38(5):505-513. doi:10.1111/ijlh.12528
73. Cini M, Legnani C, Padrini R, et al. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register. Int J Lab Hematol . 2020;42(2):214-222. doi:10.1111/ijlh.13159
74. Kubitza D, Willmann S, Becka M, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: An EINSTEIN-Jr phase i study. Thromb J . 2018;16(1):1-13. doi:10.1186/s12959-018-0186-0
75. Kassir R, Debs T, Blanc P, et al. Complications of bariatric surgery: Presentation and emergency management. Int J Surg . 2016;27:77-81. doi:10.1016/j.ijsu.2016.01.067
76. Thereaux J, Lesuffleur T, Czernichow S, et al. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol . 2019;7(10):786-795. doi:10.1016/S2213-8587(19)30191-3
77. Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery.Surg Obes Relat Dis . 2006;2(4):455-459. doi:10.1016/j.soard.2006.03.004
78. D’Hondt MA, Pottel H, Devriendt D, Van Rooy F, Vansteenkiste F. Can a short course of prophylactic low-dose proton pump inhibitor therapy prevent stomal ulceration after laparoscopic Roux-en-Y gastric bypass?Obes Surg . 2010;20(5):595-599. doi:10.1007/s11695-009-0062-x
79. Gumbs AA, Duffy AJ, Bell RL. Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass. Surg Obes Relat Dis . 2006;2(4):460-463. doi:10.1016/j.soard.2006.04.233
80. Wu Chao Ying V, Song SH, J. Khan K, et al. Prophylactic PPI help reduce marginal ulcers after gastric bypass surgery: a systematic review and meta-analysis of cohort studies. Surg Endosc . 2015;29(5):1018-1023. doi:10.1007/s00464-014-3794-1
81. Garrido AB, Rossi M, Lima SE, Brenner AS, Gomes CAR. Early marginal ulcer following Roux-en-Y gastric bypass under proton pump inhibitor treatment - Prospective multicentric study. Arq Gastroenterol . 2010;47(2):130-134. doi:10.1590/S0004-28032010000200003
82. Kang X, Zurita-Macias L, Hong D, Cadeddu M, Anvari M, Gmora S. A comparison of 30-day versus 90-day proton pump inhibitor therapy in prevention of marginal ulcers after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis . 2016;12(5):1003-1007. doi:10.1016/j.soard.2015.11.010
83. Coblijn UK, Lagarde SM, De Castro SMM, Kuiken SD, Van Tets WF, Van Wagensveld BA. The influence of prophylactic proton pump inhibitor treatment on the development of symptomatic marginal ulceration in Roux-en-Y gastric bypass patients: A historic cohort study. Surg Obes Relat Dis . 2016;12(2):246-252. doi:10.1016/j.soard.2015.04.022
84. Plaeke P, Ruppert M, Hubens G. Benefits of prophylactic proton pump inhibitors after Roux-en-Y gastric bypass surgery a retrospective study.Acta Chir Belg . 2015;115(4):273-278. doi:10.1080/00015458.2015.11681111
85. Hakkarainen TW, Steele SR, Bastaworous A, et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure A report from Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg . 2015;150(3):223-228. doi:10.1001/jamasurg.2014.2239
86. Sasse KC, Ganser J, Kozar M, et al. Seven cases of gastric perforation in Roux-en-Y gastric bypass patients: What lessons can we learn? Obes Surg . 2008;18(5):530-534. doi:10.1007/s11695-007-9335-4
87. Wendling MR, Linn JG, Keplinger KM, et al. Omental patch repair effectively treats perforated marginal ulcer following Roux-en-Y gastric bypass. Surg Endosc . 2013;27(2):384-389. doi:10.1007/s00464-012-2492-0
88. Yska JP, Gertsen S, Flapper G, Emous M, Wilffert B, van Roon EN. NSAID Use after Bariatric Surgery: a Randomized Controlled Intervention Study. Obes Surg . 2016;26(12):2880-2885. doi:10.1007/s11695-016-2218-9
89. Gambineri A, Laudisio D, Marocco C, Radellini S, Colao A, Savastano S. Female infertility: which role for obesity? Int J Obes Suppl . 2019;9(1):65-72. doi:10.1038/s41367-019-0009-1
90. Merhi ZO. Impact of bariatric surgery on female reproduction.Fertil Steril . 2009;92(5):1501-1508. doi:10.1016/j.fertnstert.2009.06.046
91. Dao T, Kuhn J, Ehmer D, Fisher T, McCarty T. Pregnancy outcomes after gastric-bypass surgery. Am J Surg . 2006;192(6):762-766. doi:10.1016/j.amjsurg.2006.08.041
92. Wittgrove AC, Jester L, Wittgrove P, Clark W. Pregnancy following gastric by-pass for morbid obesity. Obes Surg . 1998;8:461-464.
93. Patel JA, Patel NA, Thomas RL, Nelms JK, Colella JJ. Pregnancy outcomes after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis . 2008;4(1):39-45. doi:10.1016/j.soard.2007.10.008
94. Victor A, Odlind V, Kral J. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass.Gastroenterol Clin North Am . 1987;(16(3)):483-491.
95. Gerrits E, Ceulemans R, van Hee R, Hendrickx L, Totté E. Materials and MethoContraceptive Treatment after Biliopancreatic Diversion Needs Consensusds. Obes Surg . 2003;13:378-382.
96. Ciangura C, Corigliano N, Basdevant A, et al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: Three case reports. Contraception . 2011;84(6):649-651. doi:10.1016/j.contraception.2011.03.015
97. Damhof MA, Pierik E, Krens LL, Vermeer M, van Det MJ, van Roon EN. Assessment of Contraceptive Counseling and Contraceptive Use in Women After Bariatric Surgery. Obes Surg . 2019;29(12):4029-4035. doi:10.1007/s11695-019-04084-z
98. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res . 2013;161(5):421-429. doi:10.1016/j.trsl.2012.12.015
99. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes . 2003;27(8):907-911. doi:10.1038/sj.ijo.0802312
100. Bordeaux BC, Qayyum R, Yanek LR, et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol . 2010;13(2):56-62. doi:10.1111/j.1751-7141.2009.00058.x
101. Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM, Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One . 2015;10(5):1-14. doi:10.1371/journal.pone.0126767
102. Norgard NB, Monte S V., Fernandez SF, Ma Q. Aspirin responsiveness changes in obese patients following bariatric surgery. Cardiovasc Ther . 2017;35(4):2-6. doi:10.1111/1755-5922.12268
103. Norgard NB. Obesity and Altered Aspirin Pharmacology. Clin Pharmacokinet . 2018;57(6):663-672. doi:10.1007/s40262-017-0611-8
104. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications . 2008;22(3):224-228. doi:10.1016/j.jdiacomp.2007.05.002
105. Darlington A, Tello-Montoliu A, Rollini F, et al. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Thromb Haemost . 2013;111(2):258-265. doi:10.1160/TH13-07-0529
106. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of Body Mass Index to High On-Treatment Platelet Reactivity and of Failed Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol . 2009;104(11):1511-1515. doi:10.1016/j.amjcard.2009.07.015
107. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of Body Mass Index on Platelet Aggregation After Administration of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous Coronary Intervention. Am J Cardiol . 2007;100(2):203-205. doi:10.1016/j.amjcard.2007.02.081
108. Kang X, Hong D, Anvari M, Tiboni M, Amin N, Gmora S. Is Daily Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric Bypass for Obesity Surgery? Obes Surg . 2017;27(5):1261-1265. doi:10.1007/s11695-016-2462-z
109. Ma Q., Norgard N. MS. Abstract, ACCP Annual Meeting 2017. Pharmacotherapy 2017 37:12 (e142-). Pharmacother J Hum Pharmacol Drug Ther . 2017;37(12):e124-e238. doi:10.1002/phar.2052
110. Caruana JA, McCabe MN, Smith AD, Panemanglore VP, Sette Camara D. Risk of massive upper gastrointestinal bleeding in gastric bypass patients taking clopidogrel. Surg Obes Relat Dis . 2007;3(4):443-445. doi:10.1016/j.soard.2006.12.008
111. Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA, Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric bypass: Results of an international survey. Obes Surg . 2014;24(5):741-746. doi:10.1007/s11695-013-1152-3
112. Wilson JA, Romagnuolo J, Byrne TK, Morgan K, Wilson FA. Predictors of endoscopic findings after Roux-en-Y gastric bypass. Am J Gastroenterol . 2006;101(10):2194-2199. doi:10.1111/j.1572-0241.2006.00770.x
113. Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg . 2013;258(2):262-269. doi:10.1097/SLA.0b013e31827a0e82
114. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver . 2017;11(1):27-37. doi:10.5009/gnl15502
115. Rajan TM, Menon V. Psychiatric disorders and obesity: A review of association studies. J Postgrad Med . 2017;63(3):182-190. doi:10.4103/jpgm.JPGM_712_16
116. Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of Common Psychiatric Medications in a Roux-En-Y Gastric Bypass Model . Vol 46.; 2005.
117. Hamad GG, Helsel JC, Perel JM, et al. The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors. Am J Psychiatry . 2012;169(3):256-263. doi:10.1176/appi.ajp.2011.11050719
118. Marzinke MA, Petrides AK, Steele K, et al. Decreased Escitalopram Concentrations Post-Roux-en-Y Gastric Bypass Surgery. Ther Drug Monit . 2015;37:408-412.
119. Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis . 2012;8(1):62-66. doi:10.1016/j.soard.2010.12.003
120. Roerig JL, Steffen KJ, Zimmerman C, Mitchell JE, Crosby RD, Cao L. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol . 2013;33(4):479-484. doi:10.1097/JCP.0b013e3182905ffb
121. Strong AT, Sharma G, Nor Hanipah Z, et al. Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis . 2018;14(5):700-706. doi:10.1016/j.soard.2017.12.021
122. Steffen KJ, Wonderlich JA, Erickson AL, Strawsell H, Mitchell JE, Crosby RD. Comparison of warfarin dosages and international normalized ratios before and after Roux-en-Y gastric bypass surgery.Pharmacotherapy . 2015;35(9):876-880. doi:10.1002/phar.1632
123. Schullo-Feulner AM, Stoecker Z, Brown GA, Schneider J, Jones TA, Burnett B. Warfarin dosing after bariatric surgery: a retrospective study of 10 patients previously stable on chronic warfarin therapy.Clin Obes . 2014;4(2):108-115. doi:10.1111/cob.12046
124. Irwin AN, McCool KH, Delate T, Witt DM. Assessment of warfarin dosing requirements after bariatric surgery in patients requiring long-term warfarin therapy. Pharmacotherapy . 2013;33(11):1175-1183. doi:10.1002/phar.1307
125. Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis . 2013;36(1):96-101. doi:10.1007/s11239-012-0811-x